Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-1778 HCMV-TB Vaccine in Healthy Adults
NCT07818824Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VIR-1778 in Tuberculosis (TB) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of solicited local reactogenicity, Incidence of solicited systemic reactogenicity and 4 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
VIR-1778
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07818824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818824.